Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Phase 2 Trial of MLN0264 in Previously Treated Patients with Advanced or Metastatic Pancreatic Adenocarcinoma Expressing Guanylyl Cyclase C (GCC)

    Summary
    EudraCT number
    		 2014-000805-11
    Trial protocol
    		 IT   ES   BE   GB  
    Global end of trial date
    15 Jan 2016

    Results information
    Results version number
    		 v1
    This version publication date
    31 Jan 2017
    First version publication date
    31 Jan 2017
    Other versions
    		 v2

    Trial information

    		 Close Top of page
    Trial identification
    Sponsor protocol code
    C26003
    Additional study identifiers
    ISRCTN number
    		 -
    US NCT number
    		 NCT02202785
    WHO universal trial number (UTN)
    		 U1111-1155-8964
    Sponsors
    Sponsor organisation name
    Millennium Pharmaceuticals, Inc.
    Sponsor organisation address
    40 Landsdowne Street, Cambridge, MA, United States, 02139
    Public contact
    Medical Director, Takeda, +1 877-825-3327,
    Scientific contact
    Medical Director, Takeda, +1 877-825-3327, trialdisclosures@takeda.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    15 Jan 2016
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    15 Jan 2016
    Global end of trial reached?
    Yes
    Global end of trial date
    15 Jan 2016
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The purpose of this study is to assess the efficacy, safety and tolerability of MLN0264 in patients with advanced or metastatic guanylyl cyclase C (GCC)-positive adenocarcinoma of the pancreas.
    Protection of trial subjects
    All study participants were required to read and sign an Informed Consent Form.
    Background therapy
    		 -
    Evidence for comparator
    		 -
    Actual start date of recruitment
    24 Sep 2014
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Belgium: 5
    Country: Number of subjects enrolled
    Spain: 15
    Country: Number of subjects enrolled
    United Kingdom: 3
    Country: Number of subjects enrolled
    United States: 20
    Worldwide total number of subjects
    43
    EEA total number of subjects
    23
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    21
    From 65 to 84 years
    22
    85 years and over
    0

    Subject disposition

    		 Close Top of page
    Recruitment
    Recruitment details
    		 Participants took part in the study at 26 investigative sites in Belgium, Spain, United Kingdom and the United States from 24 September 2014 to 15 January 2016.

    Pre-assignment
    Screening details
    		 Participants with a diagnosis of Pancreatic adenocarcinoma were enrolled in 1 treatment group, MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    		 Yes
    Allocation method
    Not applicable
    Blinding used
    		 Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    		 MLN0264 1.8 mg/kg (GCC Low)
    Arm description
    		 MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 4 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Low (combined H-score 10-59). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.
    Arm type
    		 Experimental

    Investigational medicinal product name
    MLN0264
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for injection/infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle

    Arm title
    		 MLN0264 1.8 mg/kg (GCC Intermediate)
    Arm description
    		 MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score 60-119). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.
    Arm type
    		 Experimental

    Investigational medicinal product name
    MLN0264
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for injection/infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle

    Arm title
    		 MLN0264 1.8 mg/kg (GCC High)
    Arm description
    		 MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 6 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score >120). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.
    Arm type
    		 Experimental

    Investigational medicinal product name
    MLN0264
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Powder for solution for injection/infusion
    Routes of administration
    Intravenous use
    Dosage and administration details
    1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle

    Number of subjects in period 1
    		MLN0264 1.8 mg/kg (GCC Low) MLN0264 1.8 mg/kg (GCC Intermediate) MLN0264 1.8 mg/kg (GCC High)
    Started
    11
    15
    17
    Completed
    0
    0
    0
    Not completed
    11
    15
    17
         Consent withdrawn by subject
    -
    1
    -
         Study Terminated by Sponsor
    1
    6
    4
         Lost to follow-up
    -
    1
    -
         Reason not Specified
    10
    7
    13

    Baseline characteristics

    		 Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    MLN0264 1.8 mg/kg (GCC Low)
    Reporting group description
    		 MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 4 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Low (combined H-score 10-59). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

    Reporting group title
    MLN0264 1.8 mg/kg (GCC Intermediate)
    Reporting group description
    		 MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score 60-119). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

    Reporting group title
    MLN0264 1.8 mg/kg (GCC High)
    Reporting group description
    		 MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 6 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score >120). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

    Reporting group values
    		 MLN0264 1.8 mg/kg (GCC Low) MLN0264 1.8 mg/kg (GCC Intermediate) MLN0264 1.8 mg/kg (GCC High) Total
    Number of subjects
    		 11 15 17 43
    Age categorical
    Units: Subjects
        44 to 81 years
    		 11 15 17 43
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    		 63.1 ( 11.2 ) 65.5 ( 7.41 ) 62.9 ( 10.88 ) -
    Gender, Male/Female
    Units: Participants
        Female
    		 8 11 4 23
        Male
    		 3 4 13 20
    Race/Ethnicity, Customized
    Units: Subjects
        White
    		 9 15 17 41
        Black or African American
    		 1 0 0 1
        Not Reported
    		 1 0 0 1
    Race/Ethnicity, Customized
    Units: Subjects
        Hispanic or Latino
    		 3 1 0 4
        Not Hispanic or Latino
    		 8 14 17 39
    Study Specific Characteristic | Height
    Units: cm
        arithmetic mean (standard deviation)
    		 163 ( 13.2 ) 162.1 ( 9.54 ) 170.6 ( 8.51 ) -
    Study Specific Characteristic | Weight
    Units: kg
        arithmetic mean (standard deviation)
    		 60.98 ( 18.769 ) 63.45 ( 18.465 ) 71.2 ( 17.456 ) -
    Study Specific Characteristic | Body Surface Area
    Units: m^2
        arithmetic mean (standard deviation)
    		 1.65 ( 0.3045 ) 1.679 ( 0.2761 ) 1.827 ( 0.2575 ) -
    Subject analysis sets

    Subject analysis set title
    MLN0264 1.8 mg/kg
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.

    Subject analysis set title
    MLN0264 1.8 mg/kg
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.

    Subject analysis sets values
    		 MLN0264 1.8 mg/kg MLN0264 1.8 mg/kg
    Number of subjects
    43
    1
    Age categorical
    Units: Subjects
        44 to 81 years
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    ( )
    ( )
    Gender, Male/Female
    Units: Participants
        Female
        Male
    Race/Ethnicity, Customized
    Units: Subjects
        White
    41
    1
        Black or African American
    1
    0
        Not Reported
    1
    0
    Race/Ethnicity, Customized
    Units: Subjects
        Hispanic or Latino
    4
    0
        Not Hispanic or Latino
    39
    1
    Study Specific Characteristic | Height
    Units: cm
        arithmetic mean (standard deviation)
    ( )
    ( )
    Study Specific Characteristic | Weight
    Units: kg
        arithmetic mean (standard deviation)
    ( )
    ( )
    Study Specific Characteristic | Body Surface Area
    Units: m^2
        arithmetic mean (standard deviation)
    ( )
    ( )

    End points

    		 Close Top of page
    End points reporting groups
    Reporting group title
    MLN0264 1.8 mg/kg (GCC Low)
    Reporting group description
    		 MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 4 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Low (combined H-score 10-59). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

    Reporting group title
    MLN0264 1.8 mg/kg (GCC Intermediate)
    Reporting group description
    		 MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score 60-119). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

    Reporting group title
    MLN0264 1.8 mg/kg (GCC High)
    Reporting group description
    		 MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 6 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264. Participants with guanylyl cyclase C (GCC) protein expression=Intermediate (combined H-score >120). Total H-score 0-600 is the combined score of cytoplasmic staining 0-300 and apical staining 0-300 and is based on the percentage of tumor cells with staining intensity 1+, 2+ and 3+.

    Subject analysis set title
    MLN0264 1.8 mg/kg
    Subject analysis set type
    		 Safety analysis
    Subject analysis set description
    MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.

    Subject analysis set title
    MLN0264 1.8 mg/kg
    Subject analysis set type
    		 Sub-group analysis
    Subject analysis set description
    MLN0264 1.8 mg/kg, 30-minute intravenous (IV) infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.

    Primary: Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST)

    		 Close Top of page
    End point title
    		 Overall Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors (RECIST) [1]
    End point description
    ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the investigator using Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
    End point type
    Primary
    End point timeframe
    Day 21, every other cycle, starting with Cycle 2 until disease progression, death or study closure (Up to 16 months)
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned for this endpoint.
    End point values
    		 MLN0264 1.8 mg/kg (GCC Low) MLN0264 1.8 mg/kg (GCC Intermediate) MLN0264 1.8 mg/kg (GCC High)
    Number of subjects analysed
    11
    13
    15
    Units: percentage of participants
    0
    8
    0
    No statistical analyses for this end point

    Secondary: Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings

    		 Close Top of page
    End point title
    		 Number of Participants With Potentially Clinically Significant Laboratory Evaluation Findings
    End point description
    Participants with at least one post-baseline potentially clinically significant serum chemistry, hematology, coagulation or urinalysis result. Clinically significant results are those that were assessed by the investigator to be Grade 3 or higher using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Grade 3=severe, Grade 4=life threatening or disabling and Grade 5=Death.
    End point type
    Secondary
    End point timeframe
    Day 1 of each 21 day cycle and 30 days after the last dose of study medication (Up to 7.9 months)
    End point values
    		 MLN0264 1.8 mg/kg
    Number of subjects analysed
    43
    Units: Participants
        Chemistry
    20
        Hematology
    16
        Coagulation
    23
        Urinalysis
    0
    No statistical analyses for this end point

    Secondary: Number of Participants With Potentially Clinically Significant Vital Signs Findings

    		 Close Top of page
    End point title
    		 Number of Participants With Potentially Clinically Significant Vital Signs Findings
    End point description
    Participants with at least one potentially clinically significant post-baseline vital sign finding including measurements of diastolic and systolic blood pressure, heart rate, and oral temperature.
    End point type
    Secondary
    End point timeframe
    Day 1 of each 21 day cycle and 30 days after the last dose of study medication (Up to 7.9 months)
    End point values
    		 MLN0264 1.8 mg/kg
    Number of subjects analysed
    43
    Units: Participants
    0
    No statistical analyses for this end point

    Secondary: Progression Free Survival (PFS)

    		 Close Top of page
    End point title
    		 Progression Free Survival (PFS)
    End point description
    PFS is defined as the time in days from the date of first study drug administration to the date of first documentation of disease progression or death.
    End point type
    Secondary
    End point timeframe
    Day 21 of every other 21-day cycle starting with Cycle 2, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (Up to 13.9 months)
    End point values
    		 MLN0264 1.8 mg/kg (GCC Low) MLN0264 1.8 mg/kg (GCC Intermediate) MLN0264 1.8 mg/kg (GCC High)
    Number of subjects analysed
    11
    13
    15
    Units: days
        median (full range (min-max))
    39 (9 to 82)
    42 (21 to 218)
    41 (16 to 137)
    No statistical analyses for this end point

    Secondary: Duration of Response

    		 Close Top of page
    End point title
    		 Duration of Response
    End point description
    Duration of response is defined as the time from the date of first documentation of a Partial Response or better to the date of first documentation of disease progression or relapse based on investigator assessment using RECIST version 1.1 guidelines.
    End point type
    Secondary
    End point timeframe
    From first documented response until disease progression (Up to 16 months)
    End point values
    		 MLN0264 1.8 mg/kg
    Number of subjects analysed
    1
    Units: days
        median (full range (min-max))
    103 (103 to 103)
    No statistical analyses for this end point

    Secondary: Disease Control Rate

    		 Close Top of page
    End point title
    		 Disease Control Rate
    End point description
    Disease control rate is defined as the percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) with a minimum of 12 weeks' duration. Investigator response is based on the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. CR: Disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30% decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), taking as reference the smallest sum longest diameter (LD) since the treatment started.
    End point type
    Secondary
    End point timeframe
    Day 21 of every other 21-day cycle starting with Cycle 2, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (Up to 13.9 months)
    End point values
    		 MLN0264 1.8 mg/kg (GCC Low) MLN0264 1.8 mg/kg (GCC Intermediate) MLN0264 1.8 mg/kg (GCC High)
    Number of subjects analysed
    11
    13
    15
    Units: percentage of participants
    0
    23
    20
    No statistical analyses for this end point

    Secondary: Overall Survival (OS)

    		 Close Top of page
    End point title
    		 Overall Survival (OS)
    End point description
    Overall survival is defined as the time in days from the date of first study drug administration to the date of death.
    End point type
    Secondary
    End point timeframe
    Until death or 6 months after the last patient completes treatment—whichever occurs first (Up to 16 months)
    End point values
    		 MLN0264 1.8 mg/kg (GCC Low) MLN0264 1.8 mg/kg (GCC Intermediate) MLN0264 1.8 mg/kg (GCC High)
    Number of subjects analysed
    11
    15
    17
    Units: days
        median (full range (min-max))
    162 (36 to 282)
    140 (43 to 443)
    162 (49 to 435)
    No statistical analyses for this end point

    Secondary: Cmax: Maximum Observed Serum Concentration for MLN0264

    		 Close Top of page
    End point title
    		 Cmax: Maximum Observed Serum Concentration for MLN0264
    End point description
    Cmax was not a pre-specified secondary outcome measure. No data was collected.
    End point type
    Secondary
    End point timeframe
    Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose.
    End point values
    		 MLN0264 1.8 mg/kg
    Number of subjects analysed
    0 [2]
    Units: μg/mL
        arithmetic mean (standard deviation)
    ( )
    Notes
    [2] - No data was collected for this analysis due to early termination.
    No statistical analyses for this end point

    Secondary: Serum Concentration of Monomethyl Auristatin E (MMAE)

    		 Close Top of page
    End point title
    		 Serum Concentration of Monomethyl Auristatin E (MMAE)
    End point description
    Blood samples were collected and sent to a laboratory to be tested for MMAE.
    End point type
    Secondary
    End point timeframe
    Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose.
    End point values
    		 MLN0264 1.8 mg/kg
    Number of subjects analysed
    43
    Units: ng/mL
    arithmetic mean (standard deviation)
        Cycle 1 Day 1, Pre-Dose
    0 ( 0 )
        Cycle 1 Day 1, 10 Minutes Post-Dose
    0.296 ( 0.1624 )
        Cycle 1 Day 1, 4 Hours Post-Dose
    2.438 ( 1.3015 )
        Cycle 1 Day 3, 48 Hours Post-Dose (n=41)
    5.202 ( 2.811 )
        Cycle 1 Day 4, 72 Hours Post-Dose (n=39)
    4.918 ( 2.3653 )
        Cycle 1 Day 8, 168 Hours Post-Dose (n=43)
    2.994 ( 2.1173 )
        Cycle 1 Day 15, 336 Hours Post-Dose (n=37)
    0.58 ( 0.5073 )
        Cycle 2 Day 1, Pre-Dose (n=37)
    0.128 ( 0.1304 )
        Cycle 2 Day 1, 10 Minutes Post-Dose (n=37)
    0.405 ( 0.3351 )
        Cycle 2 Day 1, 4 Hours Post-Dose (n=37)
    2.665 ( 1.6053 )
        Cycle 2 Day 3, 48 Hours Post-Dose (n=34)
    6.223 ( 3.5926 )
        Cycle 2 Day 4, 72 Hours Post-Dose (n=32)
    5.808 ( 3.6296 )
        Cycle 2 Day 8, 168 Hours Post-Dose (n=34)
    2.789 ( 2.0437 )
        Cycle 2 Day 15, 336 Hours Post-Dose (n=28)
    0.56 ( 0.5332 )
        Cycle 3 Day 1, Pre-Dose (n=9)
    0.145 ( 0.1318 )
        Cycle 3 Day 1, 10 Minutes Post-Dose (n=9)
    0.395 ( 0.3514 )
        Cycle 3 Day 1, 4 Hours Post-Dose (n=9)
    2.237 ( 1.6402 )
        Cycle 3 Day 3, 48 Hours Post-Dose (n=8)
    6.563 ( 5.2034 )
        Cycle 3 Day 4, 72 Hours Post-Dose (n=8)
    6.563 ( 6.2902 )
        Cycle 3 Day 8, 168 Hours Post-Dose (n=7)
    2.826 ( 2.0234 )
        Cycle 3 Day 15, 336 Hours Post-Dose (n=7)
    1.155 ( 1.2808 )
        Cycle 4 Day 1, Pre-Dose (n=7)
    0.232 ( 0.2877 )
        Cycle 4 Day 1, 10 Minutes Post-Dose (n=7)
    0.446 ( 0.4029 )
        Cycle 5 Day 1, Pre-Dose (n=5)
    0.09 ( 0.0594 )
        Cycle 5 Day 1, 10 Minutes Post-Dose (n=5)
    0.249 ( 0.1004 )
        Cycle 6 Day 1, Pre-Dose (n=5)
    0.105 ( 0.0469 )
        Cycle 6 Day 1, 10 Minutes Post-Dose (n=5)
    0.269 ( 0.1037 )
        Cycle 6 Day 4, 72 Hours Post-Dose (n=5)
    4.234 ( 1.3134 )
        Cycle 6 Day 8, 168 Hours Post-Dose (n=5)
    2.002 ( 0.9691 )
        Cycle 7 Day 1, Pre-Dose (n=2)
    0.125 ( 0.0365 )
        Cycle 7 Day 1, 10 Minutes Post-Dose (n=2)
    0.277 ( 0.0806 )
        Cycle 8 Day 1, Pre-Dose (n=2)
    0.108 ( 0.0288 )
        Cycle 8 Day 1, 10 Minute Post-Dose (n=2)
    0.257 ( 0.0481 )
        Cycle 9 Day 1, Pre-Dose (n=2)
    0.05 ( 0.019 )
        Cycle 9 Day 1, 10 Minutes Post-Dose (n=2)
    0.19 ( 0.0361 )
        Cycle 10 Day 1, Pre-Dose (n=1)
    0.132 ( 0 )
        Cycle 10 Day 1, 10 Minutes Post-Dose (n=1)
    0.385 ( 0 )
        End of Treatment (n=27)
    0.137 ( 0.1695 )
    No statistical analyses for this end point

    Secondary: Guanylyl Cyclase C (GCC) H-score assessed by immunohistochemistry (IHC)

    		 Close Top of page
    End point title
    		 Guanylyl Cyclase C (GCC) H-score assessed by immunohistochemistry (IHC)
    End point description
    GCC H-score is based on the sum of the 0 to 300 H-score for cytoplasmic staining and the 0 to 300 H-score for apical staining for a total possible H-score 0 to 600. Separate consent is required to obtain archival tumor specimens for GCC expression assessment prior to screening.

    End point type
    Secondary
    End point timeframe
    From pre-screening through end of study (approximately 18 months)
    End point values
    		 MLN0264 1.8 mg/kg (GCC Low) MLN0264 1.8 mg/kg (GCC Intermediate) MLN0264 1.8 mg/kg (GCC High)
    Number of subjects analysed
    11
    15
    17
    Units: Scores on a scale
    arithmetic mean (full range (min-max))
        Guanylyl Cyclase C (GCC) H-score Assessed by Immun
    29.6 (10 to 55)
    84 (60 to 110)
    204.2 (120 to 355)
    No statistical analyses for this end point

    Secondary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    		 Close Top of page
    End point title
    		 Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
    End point description
    An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product; the untoward medical occurrence does not necessarily have a causal relationship with this treatment. An SAE is defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.
    End point type
    Secondary
    End point timeframe
    From the first dose through 30 days after the last dose of study medication (Up to 7.9 months)
    End point values
    		 MLN0264 1.8 mg/kg (GCC Low) MLN0264 1.8 mg/kg (GCC Intermediate) MLN0264 1.8 mg/kg (GCC High)
    Number of subjects analysed
    11
    15
    17
    Units: Participants
        AEs
    11
    15
    17
        SAEs
    3
    7
    9
    No statistical analyses for this end point

    Secondary: MLN0264 Serum Concentrations

    		 Close Top of page
    End point title
    		 MLN0264 Serum Concentrations
    End point description
    Blood samples were collected and sent to a laboratory to be tested for serum concentrations of MLN0264.
    End point type
    Secondary
    End point timeframe
    Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose.
    End point values
    		 MLN0264 1.8 mg/kg
    Number of subjects analysed
    43
    Units: μg/mL
    arithmetic mean (standard deviation)
        Cycle 1 Day 1, Pre-Dose
    0 ( 0 )
        Cycle 1 Day 1, 10 Minutes Post-Dose
    36.647 ( 10.0936 )
        Cycle 1 Day 1, 4 Hours Post-Dose
    27.898 ( 8.4886 )
        Cycle 1 Day 3, 48 Hours Post-Dose (n=41)
    6.95 ( 1.9173 )
        Cycle 1 Day 4, 72 Hours Post-Dose (n=39)
    4.758 ( 1.5349 )
        Cycle 1 Day 8, 168 Hours Post-Dose (n=43)
    1.563 ( 0.5818 )
        Cycle 1 Day 15, 336 Hours Post-Dose (n=37)
    0.582 ( 0.2331 )
        Cycle 2 Day 1, Pre-Dose (n=37)
    0.261 ( 0.1643 )
        Cycle 2 Day 1, 10 Minutes Post-Dose (n=37)
    30.856 ( 9.9483 )
        Cycle 2 Day 1, 4 Hours Post-Dose (n=37)
    26.691 ( 7.9664 )
        Cycle 2 Day 3, 48 Hours Post-Dose (n=35)
    7.021 ( 2.4977 )
        Cycle 2 Day 4, 72 Hours Post-Dose (n=32)
    4.432 ( 1.6115 )
        Cycle 2 Day 8, 168 Hours Post-Dose (n=34)
    1.681 ( 0.78 )
        Cycle 2 Day 15, 336 Hours Post-Dose (n=27)
    0.692 ( 0.3038 )
        Cycle 3 Day 1, Pre-Dose (n=9)
    0.431 ( 0.1481 )
        Cycle 3 Day 1, 10 Minutes Post-Dose (n=9)
    34.978 ( 5.335 )
        Cycle 3 Day 1, 4 Hours Post-Dose (n=9)
    26.393 ( 3.3557 )
        Cycle 3 Day 3, 48 Hours Post-Dose (n=8)
    9.486 ( 2.9593 )
        Cycle 3 Day 4, 72 Hours Post-Dose (n=8)
    6.579 ( 1.8102 )
        Cycle 3 Day 8, 168 Hours Post-Dose (n=7)
    1.701 ( 0.4201 )
        Cycle 3 Day 15, 336 Hours Post-Dose (n=7)
    0.89 ( 0.2276 )
        Cycle 4 Day 1, Pre-Dose (n=7)
    0.49 ( 0.1881 )
        Cycle 4 Day 1, 10 Minutes Post-Dose (n=7)
    37.166 ( 9.3823 )
        Cycle 5 Day 1, Pre-Dose (n=5)
    0.446 ( 0.2197 )
        Cycle 5 Day 1, 10 Minutes Post-Dose (n=5)
    31.06 ( 8.3802 )
        Cycle 6 Day 1, Pre-Dose (n=5)
    0.412 ( 0.2183 )
        Cycle 6 Day 1, 10 Minutes Post-Dose (n=5)
    23.204 ( 12.9564 )
        Cycle 6 Day 4, 72 Hours Post-Dose (n=5)
    4.689 ( 0.9286 )
        Cycle 6 Day 8, 168 Hours Post-Dose (n=5)
    1.41 ( 0.2504 )
        Cycle 7 Day 1, Pre-Dose (n=2)
    0.277 ( 0.0863 )
        Cycle 7 Day 1, 10 Minutes Post-Dose (n=2)
    34.56 ( 6.5337 )
        Cycle 8 Day 1, Pre-Dose (n=2)
    2.047 ( 2.6517 )
        Cycle 8 Day 1, 10 Minute Post-Dose (n=2)
    27.12 ( 4.8649 )
        Cycle 9 Day 1, Pre-Dose (n=2)
    0.178 ( 0.0467 )
        Cycle 9 Day 1, 10 Minutes Post-Dose (n=2)
    31.88 ( 0.4808 )
        Cycle 10 Day 1, Pre-Dose (n=1)
    0.207 ( 0 )
        Cycle 10 Day 1, 10 Minutes Post-Dose (n=1)
    20.86 ( 0 )
        End of Treatment (n=27)
    0.324 ( 0.2618 )
    No statistical analyses for this end point

    Secondary: Serum Concentration of Total Antibodies (Conjugated and Unconjugated)

    		 Close Top of page
    End point title
    		 Serum Concentration of Total Antibodies (Conjugated and Unconjugated)
    End point description
    Blood samples were collected and sent to a laboratory to be tested for conjugated and unconjugated antibodies.
    End point type
    Secondary
    End point timeframe
    Cycles 1-3 predose and 10 minutes, 4 hours, and 3, 4, 8 and 15 days postdose. Cycles 4+ predose, 10 minutes, 4 hours, and 4 and 8 days postdose.
    End point values
    		 MLN0264 1.8 mg/kg
    Number of subjects analysed
    43
    Units: μg/mL
    arithmetic mean (standard deviation)
        Cycle 1 Day 1, Pre-Dose
    0 ( 0 )
        Cycle 1 Day 1, 10 Minutes Post-Dose
    37.599 ( 9.4299 )
        Cycle 1 Day 1, 4 Hours Post-Dose
    32.974 ( 8.1824 )
        Cycle 1 Day 3, 48 Hours Post-Dose (n=41)
    14.051 ( 4.0368 )
        Cycle 1 Day 4, 72 Hours Post-Dose (n=39)
    10.546 ( 3.6488 )
        Cycle 1 Day 8, 168 Hours Post-Dose (n=43)
    5.252 ( 1.7703 )
        Cycle 1 Day 15, 336 Hours Post-Dose (n=37)
    2.958 ( 1.1577 )
        Cycle 2 Day 1, Pre-Dose (n=37)
    1.668 ( 0.7608 )
        Cycle 2 Day 1, 10 Minutes Post-Dose (n=37)
    35.963 ( 10.9226 )
        Cycle 2 Day 1, 4 Hours Post-Dose (n=37)
    32.134 ( 9.7822 )
        Cycle 2 Day 3, 48 Hours Post-Dose (n=35)
    14.194 ( 4.8398 )
        Cycle 2 Day 4, 72 Hours Post-Dose (n=32)
    10.948 ( 4.2741 )
        Cycle 2 Day 8, 168 Hours Post-Dose (n=34)
    6.312 ( 2.7008 )
        Cycle 2 Day 15, 336 Hours Post-Dose (n=27)
    3.923 ( 1.7465 )
        Cycle 3 Day 1, Pre-Dose (n=9)
    2.654 ( 1.0757 )
        Cycle 3 Day 1, 10 Minutes Post-Dose (n=9)
    39.5 ( 6.058 )
        Cycle 3 Day 1, 4 Hours Post-Dose (n=9)
    37.549 ( 8.2628 )
        Cycle 3 Day 3, 48 Hours Post-Dose (n=8)
    19.181 ( 3.726 )
        Cycle 3 Day 4, 72 Hours Post-Dose (n=8)
    15.808 ( 2.0101 )
        Cycle 3 Day 8, 168 Hours Post-Dose (n=7)
    6.631 ( 3.8091 )
        Cycle 3 Day 15, 336 Hours Post-Dose (n=7)
    5.279 ( 1.9171 )
        Cycle 4 Day 1, Pre-Dose (n=7)
    3.252 ( 1.3859 )
        Cycle 4 Day 1, 10 Minutes Post-Dose (n=7)
    42.194 ( 8.8085 )
        Cycle 5 Day 1, Pre-Dose (n=5)
    2.734 ( 1.2045 )
        Cycle 5 Day 1, 10 Minutes Post-Dose (n=5)
    44.244 ( 27.1286 )
        Cycle 6 Day 1, Pre-Dose (n=5)
    2.854 ( 1.7255 )
        Cycle 6 Day 1, 10 Minutes Post-Dose (n=5)
    36.304 ( 12.1646 )
        Cycle 6 Day 4, 72 Hours Post-Dose (n=5)
    12.667 ( 3.4384 )
        Cycle 6 Day 8, 168 Hours Post-Dose (n=5)
    8.04 ( 3.1264 )
        Cycle 7 Day 1, Pre-Dose (n=2)
    1.997 ( 0.7877 )
        Cycle 7 Day 1, 10 Minutes Post-Dose (n=2)
    37.13 ( 4.9922 )
        Cycle 8 Day 1, Pre-Dose (n=2)
    1.901 ( 0.5834 )
        Cycle 8 Day 1, 10 Minute Post-Dose (n=2)
    66.24 ( 43.7558 )
        Cycle 9 Day 1, Pre-Dose (n=2)
    1.462 ( 0.4547 )
        Cycle 9 Day 1, 10 Minutes Post-Dose (n=2)
    34.79 ( 2.0789 )
        Cycle 10 Day 1, Pre-Dose (n=1)
    1.282 ( 0 )
        Cycle 10 Day 1, 10 Minutes Post-Dose (n=1)
    26.32 ( 0 )
        End of Treatment (n=27)
    2 ( 1.248 )
    No statistical analyses for this end point

    Secondary: Percentage of Participants with Reduction from Baseline in Tumor Size

    		 Close Top of page
    End point title
    		 Percentage of Participants with Reduction from Baseline in Tumor Size
    End point description
    The percentage of participants with the best percentage of tumor reduction from baseline in the sum of the diameter was calculated
    End point type
    Secondary
    End point timeframe
    Day 21 of each 21-day cycle, 30 days after the last dose of study medication, and then every 12 weeks for up to an additional 6 months (Approximately 13.9 months)
    End point values
    		 MLN0264 1.8 mg/kg (GCC Low) MLN0264 1.8 mg/kg (GCC Intermediate) MLN0264 1.8 mg/kg (GCC High)
    Number of subjects analysed
    11
    13
    15
    Units: percentage of participants
    50
    64
    73
    No statistical analyses for this end point

    Secondary: Number of Participants with Antitherapeutic Antibodies (ATA)

    		 Close Top of page
    End point title
    		 Number of Participants with Antitherapeutic Antibodies (ATA)
    End point description
    Blood samples were collected to assess the immunogenicity of MLN0264 (ATA development) using a laboratory test. Neutralizing ATA assessment was performed for ATA-positive samples only.
    End point type
    Secondary
    End point timeframe
    Pre-dose of each 21 day cycle and 30 days after last dose of study medication (Up to 7.9 months)
    End point values
    		 MLN0264 1.8 mg/kg (GCC Low) MLN0264 1.8 mg/kg (GCC Intermediate) MLN0264 1.8 mg/kg (GCC High)
    Number of subjects analysed
    11
    15
    17
    Units: Participants
    0
    0
    0
    No statistical analyses for this end point

    Adverse events

    		 Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From the first dose through 30 days after the last dose of study drug (Up to 7.9 Months)
    Adverse event reporting additional description
    At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
    Assessment type
    		 Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    		 MedDRA
    Dictionary version
    18.0
    Reporting groups
    Reporting group title
    MLN0264 1.8 mg/kg
    Reporting group description
    		 MLN0264 1.8 mg/kg, 30-minute IV infusion, Day 1 of each 21-day cycle, for up to 1 year or until disease progression or unacceptable toxicity occurs (Up to 10 cycles). The dose may be decreased, delayed or discontinued in participants who develop treatment-associated nonhematologic and hematologic toxicity to MLN0264.

    Serious adverse events
    		 MLN0264 1.8 mg/kg
    Total subjects affected by serious adverse events
         subjects affected / exposed
    19 / 43 (44.19%)
         number of deaths (all causes)
    4
         number of deaths resulting from adverse events
    Nervous system disorders
    Cerebral ischaemia
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Presyncope
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Blood and lymphatic system disorders
    Neutropenia
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Febrile neutropenia
         subjects affected / exposed
    2 / 43 (4.65%)
         occurrences causally related to treatment / all
    2 / 2
         deaths causally related to treatment / all
    0 / 0
    General disorders and administration site conditions
    Device failure
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    General physical health deterioration
    Additional description: One treatment-emergent death occurred during treatment and is not related.
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Gastrointestinal disorders
    Intestinal obstruction
         subjects affected / exposed
    4 / 43 (9.30%)
         occurrences causally related to treatment / all
    1 / 4
         deaths causally related to treatment / all
    0 / 0
    Small intestinal obstruction
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Vomiting
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Abdominal pain
         subjects affected / exposed
    2 / 43 (4.65%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Ascites
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatobiliary disorders
    Cholangitis
    Additional description: One treatment-emergent death occurred during treatment and is not related.
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 1
    Hyperbilirubinaemia
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Hepatic failure
    Additional description: One treatment-emergent death occurred during treatment and is not related.
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    Bile duct obstruction
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Respiratory failure
    Additional description: One treatment-emergent death occurred during treatment and is not related.
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 1
    Pulmonary embolism
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Infections and infestations
    Candida sepsis
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Escherichia infection
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 2
         deaths causally related to treatment / all
    0 / 0
    Biliary tract infection
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Metabolism and nutrition disorders
    Hyponatraemia
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    1 / 1
         deaths causally related to treatment / all
    0 / 0
    Hyperglycaemia
         subjects affected / exposed
    1 / 43 (2.33%)
         occurrences causally related to treatment / all
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    		 MLN0264 1.8 mg/kg
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    42 / 43 (97.67%)
    Vascular disorders
    Hypertension
         subjects affected / exposed
    3 / 43 (6.98%)
         occurrences all number
    8
    General disorders and administration site conditions
    Asthenia
         subjects affected / exposed
    9 / 43 (20.93%)
         occurrences all number
    11
    Fatigue
         subjects affected / exposed
    16 / 43 (37.21%)
         occurrences all number
    22
    Oedema peripheral
         subjects affected / exposed
    3 / 43 (6.98%)
         occurrences all number
    5
    Pyrexia
         subjects affected / exposed
    6 / 43 (13.95%)
         occurrences all number
    11
    Pain
         subjects affected / exposed
    4 / 43 (9.30%)
         occurrences all number
    4
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    5 / 43 (11.63%)
         occurrences all number
    5
    Psychiatric disorders
    Insomnia
         subjects affected / exposed
    4 / 43 (9.30%)
         occurrences all number
    4
    Anxiety
         subjects affected / exposed
    3 / 43 (6.98%)
         occurrences all number
    4
    Investigations
    Weight decreased
         subjects affected / exposed
    4 / 43 (9.30%)
         occurrences all number
    4
    Blood alkaline phosphatase increased
         subjects affected / exposed
    4 / 43 (9.30%)
         occurrences all number
    4
    Nervous system disorders
    Headache
         subjects affected / exposed
    3 / 43 (6.98%)
         occurrences all number
    3
    Neuropathy peripheral
         subjects affected / exposed
    5 / 43 (11.63%)
         occurrences all number
    8
    Blood and lymphatic system disorders
    Thrombocytopenia
         subjects affected / exposed
    3 / 43 (6.98%)
         occurrences all number
    3
    Anaemia
         subjects affected / exposed
    6 / 43 (13.95%)
         occurrences all number
    7
    Neutropenia
         subjects affected / exposed
    10 / 43 (23.26%)
         occurrences all number
    14
    Gastrointestinal disorders
    Abdominal distension
         subjects affected / exposed
    4 / 43 (9.30%)
         occurrences all number
    5
    Constipation
         subjects affected / exposed
    14 / 43 (32.56%)
         occurrences all number
    16
    Abdominal pain upper
         subjects affected / exposed
    4 / 43 (9.30%)
         occurrences all number
    4
    Abdominal pain
         subjects affected / exposed
    19 / 43 (44.19%)
         occurrences all number
    23
    Diarrhoea
         subjects affected / exposed
    5 / 43 (11.63%)
         occurrences all number
    5
    Dry mouth
         subjects affected / exposed
    3 / 43 (6.98%)
         occurrences all number
    3
    Dyspepsia
         subjects affected / exposed
    5 / 43 (11.63%)
         occurrences all number
    6
    Nausea
         subjects affected / exposed
    17 / 43 (39.53%)
         occurrences all number
    19
    Vomiting
         subjects affected / exposed
    11 / 43 (25.58%)
         occurrences all number
    15
    Skin and subcutaneous tissue disorders
    Alopecia
         subjects affected / exposed
    6 / 43 (13.95%)
         occurrences all number
    6
    Renal and urinary disorders
    Dysuria
         subjects affected / exposed
    3 / 43 (6.98%)
         occurrences all number
    3
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    4 / 43 (9.30%)
         occurrences all number
    8
    Back pain
         subjects affected / exposed
    7 / 43 (16.28%)
         occurrences all number
    9
    Infections and infestations
    Urinary tract infection
         subjects affected / exposed
    5 / 43 (11.63%)
         occurrences all number
    5
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    13 / 43 (30.23%)
         occurrences all number
    15
    Dehydration
         subjects affected / exposed
    7 / 43 (16.28%)
         occurrences all number
    16
    Hypokalaemia
         subjects affected / exposed
    5 / 43 (11.63%)
         occurrences all number
    7
    Hyponatraemia
         subjects affected / exposed
    4 / 43 (9.30%)
         occurrences all number
    4
    Hypophosphataemia
         subjects affected / exposed
    3 / 43 (6.98%)
         occurrences all number
    4

    More information

    		 Close Top of page

    Substantial protocol amendments (globally)
    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    31 Mar 2014
    Amendment 1: The purpose of this amendment was to provide clarification and ensure consistency in the Schedule of Events.

    Interruptions (globally)
    Were there any global interruptions to the trial? No

    Limitations and caveats
    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 12:16:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA